MACKAY MARTIN Ramps Up Rallybio Stakes Just After Merger, Betting on Avenzo‑Backed Upside

Insider Buying Amid a Merger: What MACKAY MARTIN’s Purchase Signals for Rallybio

On November 4, 2026, MACKAY MARTIN bought 11,607 shares of Rallybio’s common stock at $7.60, followed by two additional purchases of 3,562 shares at $2.38 and 18,055 shares at $4.45. These trades bring his holdings to 125,032 shares, a 17 % increase over the prior disclosure. The transactions occurred just days after Rallybio’s shareholders approved a merger with Avenzo Therapeutics and a reverse stock split. The timing is notable: the company’s stock had just been lowered by the split and was poised to be re‑branded as Avenzo, while a special cash distribution of $84 million was announced for 2026.

From an investor’s viewpoint, the purchase volume and price levels suggest confidence in the post‑merger value proposition. MACKAY MARTIN is a relatively low‑profile owner, but his recent activity shows a pattern of buying option grants and common shares in incremental amounts, typically aligning with corporate milestones. His latest option buy on February 18, 2026, for 18,055 shares at $3.60, and his option sale on May 13, 2025, for 28,500 shares, indicate a disciplined approach to leveraging equity incentives while staying under regulatory thresholds. The current buys—especially the $2.38 and $4.45 transactions—appear to be capitalizing on the depressed price triggered by the reverse split, potentially positioning him for upside as the newly merged entity’s share price stabilizes.

Implications for Investors and the Company’s Future

The merger with Avenzo is a transformative event that will change Rallybio’s ownership structure, cash position, and strategic focus. Avenzo’s backing brings additional capital and access to a broader pipeline, which could accelerate clinical development and market entry for Rallybio’s rare‑disease therapies. MACKAY MARTIN’s purchases, made after the announcement of a special cash distribution, may reflect an anticipation that the cash payout will be funded by Avenzo’s liquidity, thereby increasing the company’s attractiveness to shareholders.

However, the merger also introduces integration risk. If the combined entity delays product launches or faces regulatory hurdles, the stock could remain volatile. Investors should monitor post‑merger share performance, particularly the newly issued Avenzo shares that will carry Rallybio’s underlying assets. The current insider activity—coupled with the company‑wide trend of substantial buys by CFO Jonathan Lieber (44,139 shares) and CEO Stephen Uden (148,864 shares)—signals that senior management believes the merger will unlock significant value.

MACKAY MARTIN: A Profile Built on Patience and Opportunism

MACKAY MARTIN’s insider history is marked by incremental option acquisitions and timed common‑stock purchases. He first purchased 18,055 option shares in February 2026, then added a large block of 28,500 option shares in May 2025, both at low prices relative to later market levels. In the current filing, his three common‑stock buys were executed at $7.60, $2.38, and $4.45—well below the market close of $15.86. This pattern suggests a strategy of buying on market dips and holding through periods of corporate development. His post‑transaction holdings have consistently increased, reflecting a long‑term interest in Rallybio’s prospects rather than speculative short‑term gains.

Bottom Line

MACKAY MARTIN’s recent purchases come at a pivotal moment for Rallybio—a time when the company’s stock is being re‑valuated due to a merger, reverse split, and cash payout. The insider activity indicates confidence in the company’s future, especially under Avenzo’s stewardship. For investors, the buys are a subtle endorsement of the merger’s value, but they should remain vigilant to integration risks and market sentiment as the new entity moves forward.